OPKO Health Inc. (OPK)

3.17
NASDAQ : Health Technology
Prev Close 3.17
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.66 / 7.90
Avg Volume 4.89M
Exchange NASDAQ
Shares Outstanding 559.47M
Market Cap 1.69B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting OPK Put And Call Options For May 25th

Investors in OPKO Health Inc saw new options become available today, for the May 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OPK options chain for the new May 25th contracts and identified one put and one call contract of particular interest.

Short Interest In OPKO Health Makes 13.7% Move

Short Interest In OPKO Health Makes 13.7% Move

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 7,902,565 share increase in total short interest for OPKO Health Inc , to 65,405,998, an increase of 13.74% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

The Truth About Trade: Cramer's 'Mad Money' Recap (Friday 3/2/18)

The Truth About Trade: Cramer's 'Mad Money' Recap (Friday 3/2/18)

From corporate tax breaks to tariffs, Jim Cramer puts it in perspective and outlines your game plan for next week.

Snap, Vail Resorts, Raymond James: 'Mad Money' Lightning Round

Snap, Vail Resorts, Raymond James: 'Mad Money' Lightning Round

Jim Cramer spotlights Snap, Vail Resorts, Raymond James Financial, Senior Housing Properties Trust, Opko Health, Deere & Co., AFLAC, Seagate Technology.

OPKO Health Reports 2017 Fourth Quarter Business Highlights And Financial Results

OPKO Health Reports 2017 Fourth Quarter Business Highlights And Financial Results

Conference Call begins today at 4:30 p.m. Eastern Time

OPKO'S GeneDx Announces Research Collaboration With Radboud University Medical Center

OPKO'S GeneDx Announces Research Collaboration With Radboud University Medical Center

Aimed at identifying novel genes and pathways to help manage human genetic diseases

First Week Of OPK February 2018 Options Trading

First Week Of OPK February 2018 Options Trading

Investors in OPKO Health Inc saw new options begin trading this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OPK options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

OPKO Health Enrolls First Patient In Phase 2B Study Of OPK88004 To Treat Benign Prostatic Hypertrophy

OPKO Health Enrolls First Patient In Phase 2B Study Of OPK88004 To Treat Benign Prostatic Hypertrophy

Enlarged Prostate Affects Approximately 50 Million Men in the U.S.

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer highlights Home Depot, Lowe's, The Blackstone Group, Capital Senior Living, Cypress Semiconductor.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

Xenetic Biosciences Reports 2017 Third Quarter Financial Results And Provides Corporate Update

Xenetic Biosciences Reports 2017 Third Quarter Financial Results And Provides Corporate Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Enters Into Sublicense Agreement Related To Its PolyXen™ Technology With Baxalta Inc., A Wholly-owned Subsidiary Of Shire Plc

Xenetic Biosciences Enters Into Sublicense Agreement Related To Its PolyXen™ Technology With Baxalta Inc., A Wholly-owned Subsidiary Of Shire Plc

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Xenetic Biosciences Appoints Jeffrey F. Eisenberg As Chief Executive Officer

Xenetic Biosciences Appoints Jeffrey F. Eisenberg As Chief Executive Officer

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

OPKO Health Licensee TESARO Announces FDA Approval Of VARUBI® IV For Delayed Nausea And Vomiting Associated With Chemotherapy

OPKO Health Licensee TESARO Announces FDA Approval Of VARUBI® IV For Delayed Nausea And Vomiting Associated With Chemotherapy

OPKO to receive tiered double-digit royalties on product sales

OPKO Health Enters Into Exclusive Agreement With Japan Tobacco To Develop And Commercialize RAYALDEE® In Japan

OPKO Health Enters Into Exclusive Agreement With Japan Tobacco To Develop And Commercialize RAYALDEE® In Japan

OPKO to receive up to $118 million in upfront and milestone payments, plus tiered double-digit royalties on product sales

OPKO's BioReference Laboratories And The Garage Announce National Strategic Affiliation To Enhance Value-Based Care

OPKO's BioReference Laboratories And The Garage Announce National Strategic Affiliation To Enhance Value-Based Care

Providing clinicians with advanced tools to guide quality, value-based care; affiliation to be showcased during the NAACOS Fall 2017 Conference in Washington, DC from Oct. 4-6

OPKO's GeneDx To Showcase Leadership In Genetic Testing At The National Society Of Genetic Counselors And The American Society Of Human Genetics Annual Meetings

OPKO's GeneDx To Showcase Leadership In Genetic Testing At The National Society Of Genetic Counselors And The American Society Of Human Genetics Annual Meetings

Demonstrates Commitment to Scientific and Clinical Advancement with More Than 35 Poster and Podium Presentations

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences Announces Dismissal Of Annual Meeting Of Stockholders

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences Reports 2017 Second Quarter Financial Results And Provides Business Update

Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan...

TheStreet Quant Rating: D (Sell)